ATF4 and cancer: In drug-resistant NSCLC, apatinib inhibited GLS1, forcing cancer cells to initiate the amino acid response (AAR), which induced SLC1A5 expression through the transcription factor ATF4 to compensate for extracellular glutamine acquisition, and silencing ATF4 could relieve resistance [161].